Arbutus Biopharma Corporation (NASDAQ:ABUS)’s traded shares stood at 10.11 million during the last session, with the company’s beta value hitting 2.68. At the close of trading, the stock’s price was $4.10, to imply an increase of 2.50% or $0.1 in intraday trading. The ABUS share’s 52-week high remains $5.87, putting it -43.17% down since that peak but still an impressive 40.73% since price per share fell to its 52-week low of $2.43. The company has a valuation of $407.50M, with an average of 2.23 million shares in intraday trading volume over the past 10 days and average of 2.14 million shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Arbutus Biopharma Corporation (ABUS), translating to a mean rating of 2.40. Of 5 analyst(s) looking at the stock, 0 analyst(s) give ABUS a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.24.
Arbutus Biopharma Corporation (NASDAQ:ABUS) trade information
After registering a 2.50% upside in the last session, Arbutus Biopharma Corporation (ABUS) has traded red over the past five days. The stock hit a weekly high of 4.41 this Thursday, 10/07/21, jumping 2.50% in its intraday price action. The 5-day price performance for the stock is -4.43%, and 22.02% over 30 days. With these gigs, the year-to-date price performance is 15.49%. Short interest in Arbutus Biopharma Corporation (NASDAQ:ABUS) saw shorts transact 4.15 million shares and set a 3.13 days time to cover.
Analysts on Wall Street suggest a consensus price target of $6.00, implying an increase of 31.67% to the stock’s current value. The extremes give us $4.00 and $10.00 for target low and target high price respectively. As such, ABUS has been trading -143.9% off suggested target high and 2.44% from its likely low.
Arbutus Biopharma Corporation (ABUS) estimates and forecasts
Looking at statistics comparing Arbutus Biopharma Corporation share performance against respective industry, we note that the company has outperformed competitors. Arbutus Biopharma Corporation (ABUS) shares are 24.24% up over the last 6 months, with its year-to-date growth rate higher than industry average at 10.00% against 7.00%. Revenue is forecast to grow 11.10% this quarter before jumping 4.30% for the next one. The rating firms project that company’s revenue will grow 38.40% compared to the previous financial year.
Revenue forecast for the current quarter as set by 5 analysts is $2.38 million. Meanwhile, for the quarter ending Dec 2021, a total of 5 analyst(s) estimate revenue growth to $2.64 million.
Arbutus Biopharma Corporation has its next earnings report out between November 01 and November 05. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Arbutus Biopharma Corporation has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Arbutus Biopharma Corporation (NASDAQ:ABUS)’s Major holders
Arbutus Biopharma Corporation insiders hold 19.15% of total outstanding shares, with institutional holders owning 31.66% of the shares at 39.16% float percentage. In total, 31.66% institutions holds shares in the company, led by RTW Investments LP. As of Jun 29, 2021, the company held over 5.98 million shares (or 6.03% of shares), all amounting to roughly $18.11 million.
The next major institution holding the largest number of shares is Blackrock Inc. with 5.84 million shares, or about 5.88% of shares outstanding. As of the market price on Jun 29, 2021, these shares were worth $17.68 million.
We also have Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Arbutus Biopharma Corporation (ABUS) shares. Going by data provided on Mar 30, 2021, Vanguard Total Stock Market Index Fund holds roughly 1.8 million shares. This is just over 1.82% of the total shares, with a market valuation of $5.99 million. Data from the same date shows that the other fund manager holds a little less at 1.79 million, or 1.81% of the shares, all valued at about 5.42 million.